LB PHARMACEUTICALS Business Summary

LB Pharmaceuticals Inc. (LBRX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric disorders, primarily schizophrenia and bipolar depression. The company utilizes a traditional biotechnology business model, generating capital through equity markets and private placements—most recently a $100 million financing in February 2026—rather than commercial product sales. Its operations are centered on a single business segment: the clinical advancement of its lead candidate, LB-102, a methylated derivative of the antipsychotic amisulpride intended to be the first benzamide approved in the U.S. market. LBRX competes with CNS-focused peers such as Zai Lab, Aquestive Therapeutics, and Enliven Therapeutics, positioning itself as a late-stage clinical contender with a differentiated pharmacological profile compared to standard-of-care atypical antipsychotics. The leadership team is headed by CEO Heather Turner, who brings a background in corporate strategy and legal affairs from Lyell Immunopharma, and co-founder Zachary Prensky. Key management includes Chief Business Officer Gad Soffer, Chief Commercial Officer Kaya Pai Panandiker, and Senior VP of Technical Operations Richard Silva, who leads the company’s manufacturing and CMC efforts. The company’s strategic direction is guided by a board featuring industry veterans such as William Kane, former CCO of Karuna Therapeutics, and Rekha Hemrajani. LB Pharmaceuticals maintains strong institutional support from a syndicate of specialized investors, including Deep Track Capital, Pontifax, Vida Ventures, and Balyasny Asset Management, which recently anchored the firm’s transition into pivotal Phase 3 schizophrenia trials.